- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01877187
Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Lipiodol as an Imaging Biomarker of Tumor Necrosis After Transcatheter Chemoembolization Therapy in Patients With Primary and Metastatic Liver Cancer
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Smilow Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- The Johns Hopkins Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
- Childs class of A or B (up to 9).
- Hepatocellular carcinoma (HCC) is unresectable with liver-predominant disease or subject has HCC and refused surgery or subject is diagnosed hepatic metastases from any solid tumor. (Multifocal HCC is acceptable, no diffuse HCC).
- Subject is voluntarily participating in the study and has signed the informed consent.
Exclusion Criteria:
- Contraindications to doxorubicin, cisplatin, or mytomycin-c administration (or specific mixture of chemotherapy drugs to be used).
- Evidence of severe or uncontrolled systemic diseases.
- Congestive cardiac failure >NYHA class 2 MI within 6 months, active coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, unstable angina, or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial.
- Known allergy to Lipiodol (Ethiodol), poppy seed oil, or iodinated contrast agents (that cannot be adequately mitigated with pre-procedure medication).
- Main portal vein thrombosis is excluded; segmental or branch portal vein thrombosis is acceptable.
- Subject is breastfeeding.
- Subject is pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Lipiodol
Lipiodol, 10cc per TACE.
|
Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent.
In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST)
Time Frame: 30 days, 90 days, and 180 days
|
Lipiodol deposition in the tumor will be measured using non contrast CT. The images from the non contrast CT will also be correlated with RECIST response separately using contrast CT, MRI and PET imaging. Response rates taken at 30 days, 90 days, 180 days. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR): Disappearance of all target lesions Partial Response (PR): >= 30% decrease in the sum of the longest diameter of target lesions Overall Response (OR) = CR + PR |
30 days, 90 days, and 180 days
|
Baseline Enhancing Tumor and Response by RECIST Criteria
Time Frame: 30 days, 90 days, 180 days
|
Analysis of enhancing tumor (% of tumor that arterially enhances on MRI imaging) to correlate with responders/nonresponders by RECIST criteria.
Responders are subjects that demonstrated Complete Response or Partial Response by RECIST criteria.
Nonresponders are all other subjects.
|
30 days, 90 days, 180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Time Frame: 30 days, 90 days, and 180 days
|
Lipiodol deposition in the tumor will be measured using non contrast CT. The images from the non contrast CT will also be correlated with mRECIST response separately using contrast CT, MRI and PET imaging. Response rates taken at 30 days, 90 days, 180 days. Per modified Response Evaluation Criteria in Solid Tumors (mRECIST): Complete Response (CR): Disappearance of all intratumoral arterial enhancement in target lesions Partial Response (PR): At least 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions Overall Response (OR) = CR + PR |
30 days, 90 days, and 180 days
|
Baseline Enhancing Tumor and Response by mRECIST Criteria
Time Frame: 30 days, 90 days, 180 days
|
Analysis of enhancing tumor (% of tumor that arterially enhances on MRI imaging) to correlate with responders/nonresponders by mRECIST criteria.
Responders are subjects that demonstrated Complete Response or Partial Response by mRECIST criteria.
Nonresponders are all other subjects.
|
30 days, 90 days, 180 days
|
Tumor Response by World Health Organization (WHO) Criteria
Time Frame: 6 months
|
Lipiodol deposition in the tumor will be measured using non contrast CT. The images from the non contrast CT will also be correlated with WHO response separately using contrast CT, MRI and PET imaging. Response rates taken at 30 days, 90 days, 180 days. Per WHO criteria: Complete Response (CR): disappearance of all lesions for >= 4 weeks. Partial Response (PR): At least 50% decrease in sum of the products of diameters of target lesions. Overall Response: CR + PR. |
6 months
|
Baseline Enhancing Tumor and Response by WHO Criteria
Time Frame: 30 days, 90 days, 180 days
|
Analysis of enhancing tumor (% of tumor that arterially enhances on MRI imaging) to correlate with responders/nonresponders by WHO criteria.
Responders are subjects that demonstrated Complete Response or Partial Response by WHO criteria.
Nonresponders are all other subjects.
|
30 days, 90 days, 180 days
|
Tumor Response by European Association for the Study of the Liver (EASL) Criteria
Time Frame: 6 months
|
Lipiodol deposition in the tumor will be measured using non contrast CT. The images from the non contrast CT will also be correlated with EASL response separately using contrast CT, MRI and PET imaging. Response rates taken at 30 days, 90 days, 180 days. Per EASL response: Complete Response (CR): complete disappearance of enhancing tissue in target lesions Partial Response (PR): At least 50% decrease in area of enhancing tissue in target lesions. Overall Response: CR+PR |
6 months
|
Baseline Enhancing Tumor and Response by EASL Criteria
Time Frame: 30 days, 90 days, 180 days
|
Analysis of enhancing tumor (% of tumor that arterially enhances on MRI imaging) to correlate with responders/nonresponders by EASL criteria.
Responders are subjects that demonstrated Complete Response or Partial Response by EASL criteria.
Nonresponders are all other subjects.
|
30 days, 90 days, 180 days
|
Tumor Response by Quantitative European Association for the Study of the Liver (qEASL) Criteria
Time Frame: 6 months
|
Lipiodol deposition in the tumor will be measured using non contrast CT. The images from the non contrast CT will also be correlated with qEASL response separately using contrast CT, MRI and PET imaging. Response rates taken at 30 days, 90 days, 180 days. Per qEASL criteria: Complete Response (CR): Total disappearance of enhancing tumor volume in target lesions Partial Response (PR): At least 65% decrease in enhanced tumor volume after treatment. Overall Response: CR + PR |
6 months
|
Baseline Enhancing Tumor and Response by qEASL Criteria
Time Frame: 30 days, 90 days, 180 days
|
Analysis of enhancing tumor (% of tumor that arterially enhances on MRI imaging) to correlate with responders/nonresponders by qEASL criteria.
Responders are subjects that demonstrated Complete Response or Partial Response by qEASL criteria.
Nonresponders are all other subjects.
|
30 days, 90 days, 180 days
|
6-month Survival Rate of Patients With HCC and Liver Metastases Treated With Conventional TACE
Time Frame: 6 months
|
Measure the association between baseline Lipiodol deposition and the 6-month survival rate by estimating median survival for each stratum, and by testing for homogeneity using a logrank test if hazards are proportional.
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Todd Schlachter, MD, Yale University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- J12115
- NA_00074005 (OTHER: Johns Hopkins Institutional Review Board)
- HIC1601017054 (OTHER: Yale University)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cancer
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Duke UniversityCompletedPrimary Liver Cancer | Metastatic Liver Cancer From Any Cancer SiteUnited States
-
University of HawaiiGlaxoSmithKlineRecruitingAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Liver CancerUnited States
-
Célia TurcoCompletedPrimary Liver Cancer | Liver Metastases | Secondary Liver CancerFrance
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
Radboud University Medical CenterTerumo Medical CorporationCompletedPrimary Liver Cancer | Liver Cancer | Liver Metastasis Colon CancerNetherlands
-
Cardiovascular and Interventional Radiological...RecruitingPrimary Liver Cancer | Secondary Liver CancerGermany
-
Shanghai Huihe Medical Technology Co., LtdEnrolling by invitation
-
Burzynski Research InstituteTerminatedPrimary Liver CancerUnited States
Clinical Trials on Lipiodol
-
Milton S. Hershey Medical CenterGuerbetCompleted
-
University of Texas Southwestern Medical CenterRecruitingHepatocellular CarcinomaUnited States
-
Sun Yat-sen UniversityCompletedHepatocellular CarcinomaChina
-
Assistance Publique - Hôpitaux de ParisGuerbetCompleted
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; The First Hospital...Active, not recruiting
-
National Taiwan University Hospital Hsin-Chu BranchUnknown
-
Severance HospitalPusan National University Hospital; Asan Medical Center; Korea University Anam... and other collaboratorsCompletedPulmonary Lesion With Ground-glass-opacityKorea, Republic of
-
SanofiTerminatedAtrial FibrillationUnited States, Canada
-
Center Eugene MarquisRennes University HospitalCompleted